CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy
Rhea-AI Summary
CBD Life Sciences (CBDL) has announced the launch of a new 500MG Delta-8 THC gummy product, expanding its cannabinoid wellness portfolio. The lab-tested gummies, available in Blue Razz & Strawberry flavors, are manufactured in-house and will be sold through www.thecbdvault.com. The product launch aligns with growing Delta-8 market projections, expected to reach $2.1 billion by 2026.
The gummies are designed to offer various wellness benefits, including pain relief, anxiety and stress support, nausea control, appetite stimulation, and potential neuroprotective effects. Unlike Delta-9 THC, Delta-8 provides a milder psychoactive experience. Each batch undergoes independent lab testing to ensure purity, potency, and compliance.
Positive
- Product expansion in high-growth Delta-8 market projected to reach $2.1B by 2026
- In-house manufacturing and lab testing ensures quality control and higher margins
- Delta-8 products are already one of CBDL's strongest performing categories
Negative
- Operating in a highly competitive and regulated cannabinoid market
- Potential regulatory risks associated with Delta-8 THC products
- Limited distribution channel through single website
News Market Reaction
On the day this news was published, CBDL declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
With Delta-8 product revenue continuing to climb, CBDL introduces a lab-tested gummy formulation to meet surging demand in a market projected to exceed
SCOTTSDALE, AZ / ACCESS Newswire / May 28, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising force in the cannabinoid wellness industry, is proud to announce the latest addition to its growing Delta-8 product lineup: a premium, lab-tested Delta-8 THC gummy, developed in-house to ensure consistency, potency, and quality at every step.
Building on the success of its existing Delta-8 offerings, this new gummy marks another strategic milestone in CBDL's mission to dominate the cannabinoid edibles market. Crafted in a controlled lab environment, this new edible is designed for consumers who prioritize quality, effectiveness, and a clean, smooth Delta-8 experience.
"We've already seen strong performance across our Delta-8 line, and this gummy is a direct response to customer demand for more convenient, enjoyable, and effective ways to experience its benefits," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As always, we're delivering a product that's backed by science, produced in-house, and driven by results."
Delta-8 THC: Expanding the Future of Functional Wellness
Unlike traditional Delta-9 THC, Delta-8 offers a milder, clearer psychoactive experience - making it a preferred option for wellness seekers, first-time users, and individuals looking for a balanced high without anxiety.
CBDL's newly formulated Delta-8 gummies are not just about effect - they're designed to deliver real therapeutic value. Below is a breakdown of the core wellness benefits supported by research and consumer feedback:
Pain Relief
• Engages the endocannabinoid system to help regulate pain
• May reduce inflammation that contributes to chronic discomfort
Anxiety & Stress Support
• Natural calming effects to help manage daily stress and reduce anxiety
• Promotes overall mood balance without sedation
Nausea Control
• Anti-emetic potential makes it a powerful option for those undergoing chemotherapy or other nausea-inducing treatments
Appetite Stimulation
• Ideal for individuals with appetite loss or dietary imbalances related to health conditions
Neuroprotective Potential
• Early research suggests Delta-8 THC may contribute to long-term brain health through its interaction with CB1 receptors
Made In-House. Backed by Lab Testing.
Unlike many mass-produced gummies on the market, CBDL maintains full control over every phase - from formulation to packaging - in its in-house manufacturing facility. Each batch is independently lab-tested to guarantee purity, potency, and compliance, giving consumers complete confidence in what they're consuming.
Strategic Growth for Shareholders & Stakeholders
Delta-8 THC products have already proven to be one of CBDL's strongest performing categories, and this launch further solidifies the company's aggressive expansion in the high-growth cannabinoid edible space. The market for Delta-8 continues to gain national momentum, with sales projections showing compound annual growth that far outpaces many traditional supplement sectors.
"This gummy is just one part of a much larger product ecosystem we're building - focused on in-demand cannabinoids, real health outcomes, and market scalability," said Nelson.
Product Details
• Product: Delta-8 THC Gummy
• Type: Vegan, In-House Formulated, Lab-Tested
• MG per Gummy: 500MG
• Availability: Launching via www.thecbdvault.com
• Flavors: Blue Razz & Strawberry
About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is a vertically integrated health and wellness company focused on cannabinoid innovation. With a robust pipeline of CBD, Delta-8, and other hemp-derived formulations, CBDL operates across direct-to-consumer, retail, and wholesale channels - including recent distribution on Walmart Marketplace and additional platforms coming soon.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on ACCESS Newswire
FAQ
What is the strength of CBDL's new Delta-8 THC gummy?
How does CBDL ensure the quality of their Delta-8 gummies?
What are the main benefits of CBDL's Delta-8 THC gummies?
How is Delta-8 THC different from traditional Delta-9 THC?
Where can customers purchase CBDL's new Delta-8 gummies?
